Efficacy of Labetalol Combined with Enoxaparin Sodium in the Treatment of Preeclampsia and Its Effects on Pregnancy Outcomes

To evaluate the effectiveness and safety of adjunctive enoxaparin sodium in women with early-onset preeclampsia receiving labetalol-based treatment. This retrospective cohort study included 136 patients, with 68 receiving labetalol alone and 68 receiving labetalol plus enoxaparin. Propensity score overlap weighting and multivariable models were used to adjust for baseline differences. The combined-treatment group had a lower 7-day composite disease-progression rate than the labetalol group (26.5% vs 44.1%; P=0.031), higher blood pressure control at 72 hours (82.8% vs 66.1%; P=0.031), and fewer severe hypertensive episodes (median 1 vs 2; P=0.012). Pregnancy was prolonged by a median of 13 versus 8 days (P=0.006), and birth weight was higher (1,940 vs 1,735 g; P=0.009). Postpartum hemorrhage did not increase significantly. Adjunctive enoxaparin was associated with improved maternal stabilization and pregnancy outcomes without a clear safety penalty. These findings support prospective validation in multicenter studies before its routine clinical adoption.